Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCLL.L Regulatory News (CLL)

  • There is currently no data for CLL

Digital capability widened

8 May 2009 14:55

RNS Number : 9610R
Cello Group plc
08 May 2009
 



8 May 2009

Cello Group plc

Digital capability widened with increased holding in Face Group

 

Cello Group plc ("Cello" or the "Group", AIM: CLL), the leading independent market research and consulting group, has acquired an additional 30.6% in Fenix Media Limited ("Fenix Media"), taking its total holding to 50.7%. The original stake was acquired in December 2007. 

Fenix Media trades under the name Face Group (http://www.facegroup.co.uk) and has a number of leading edge digital research and co-creation products.

Mark Scott, Cello Chief Executive, commented:

"Taking a majority stake in Face Group is another important step in widening our digital capabilities. The products and services offered by Face Group are increasingly in demand from our growing range of global blue chip client base."

The Group will issue 443,792 new ordinary shares of 10p each ("Ordinary Shares") pursuant to the share purchase agreement with the vendors of Fenix Media. Application has been made for the Ordinary Shares to be admitted to trading on AIM and admission is expected to occur on 13 May 2009. The Ordinary Shares are subject to a full trading lock-in for a year and a sliding lock-in for the following two years. 

The Group has now settled all of the earn out and related liabilities that were detailed in the results announcement of 17 March 2009 as being due for settlement within one year. 

The Group's issued share capital, following this issue of 443,792 new ordinary shares will be 58,762,197 Ordinary Shares. The new Ordinary Shares will rank from admission pari passu in all respects with the existing Ordinary Shares in issue. The Group holds 237,000 Ordinary Shares in treasury at the date of this announcement. The total number of current voting rights in the Group will therefore be 58,525,197 shares.

The above figure (58,525,197 Ordinary Shares) may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change in their interest in, the Group under the FSA's Disclosure and Transparency Rules. 

Enquiries

 

Cello Group 

 

Mark Scott, Chief Executive

020 7812 8460

Mark Bentley, Finance Director

 

Singer Capital Markets

 

Nicholas How

020 3205 7620

 

 

College Hill

 

Adrian Duffield/Rozi Morris

020 7457 2020

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCUWVORKORVRAR
Date   Source Headline
20th Jul 202012:21 pmRNSForm 8.3 - Cello Health Plc
17th Jul 20209:14 amRNSForm 8.3 - Cello Health PLC
16th Jul 20205:00 pmRNSForm 8.3 - Cello Health plc
16th Jul 20208:48 amRNSForm 8.3 - Cello Health PLC
16th Jul 20207:00 amRNSForm 8.3 - Cello Health Plc
15th Jul 20203:00 pmRNSUpdate re: antitrust clearances
15th Jul 20201:44 pmRNSForm 8.3 - Cello Health Plc
15th Jul 20201:21 pmRNSHolding(s) in Company
15th Jul 20208:55 amRNSForm 8.3 - Cello Health PLC
14th Jul 20201:33 pmRNSForm 8.3 - Cello Health plc
14th Jul 20208:51 amRNSForm 8.3 - Cello Health PLC
14th Jul 20208:04 amRNSHolding(s) in Company
14th Jul 20207:01 amRNSHolding(s) in Company
13th Jul 20203:15 pmBUSForm 8.3 - Cello Health plc
13th Jul 202010:51 amBUSForm 8.3 - CELLO HEALTH PLC
13th Jul 20208:18 amRNSForm 8.3 - Cello Health PLC
13th Jul 20207:00 amRNSHolding(s) in Company
13th Jul 20207:00 amRNSPublication of Scheme Document
10th Jul 20203:20 pmRNSForm 8.3 - Cello Health Plc
10th Jul 20203:17 pmRNSForm 8.3 - Cello Health PLC
10th Jul 20203:10 pmPRNForm 8.3 - Cello Health Plc
10th Jul 20201:34 pmBUSForm 8.3 - CELLO HEALTH PLC
10th Jul 202010:11 amRNSHolding(s) in Company
10th Jul 20209:41 amRNSForm 8.3 - Cello Health Plc
10th Jul 20208:51 amRNSForm 8.3 - Cello Health PLC
9th Jul 20206:20 pmRNSUpdate on letters of intent
9th Jul 20205:38 pmRNSHolding(s) in Company
9th Jul 20203:20 pmRNSForm 8.3 - Cello Health
9th Jul 20203:17 pmRNSForm 8.3 - CELLO HEALTH PLC
9th Jul 20203:08 pmRNSForm 8.3 - Cello Health PLC
9th Jul 20203:00 pmBUSForm 8.3 - Cello Health Plc
9th Jul 202012:33 pmRNSHolding(s) in Company
9th Jul 202011:31 amRNSForm 8.3 - Cello Health Plc
9th Jul 20209:20 amRNSForm 8.3 - Cello Health plc
9th Jul 20209:10 amRNSForm 8.3 - Cello Health PLC
9th Jul 20207:00 amRNSUpdate on irrevocable undertakings
8th Jul 20203:56 pmPRNForm 8.3 - Cello Health Plc
8th Jul 20203:00 pmBUSForm 8.3 - Cello Health Plc
8th Jul 20202:00 pmRNSForm 8.3 - Cello Health Plc
8th Jul 202012:45 pmRNSForm 8.3 - Cello Health plc
8th Jul 202010:35 amRNSForm 8.3 - Cello Health PLC
8th Jul 20209:55 amRNSForm 8.3 - Cello Health plc
8th Jul 20208:54 amPRNForm 8.3 - Cello Health plc
8th Jul 20207:00 amRNSUpdate on irrevocable undertakings
8th Jul 20207:00 amRNSForm 8.3 - Cello Health PLC
7th Jul 20203:20 pmRNSForm 8.3 - Cello Health
7th Jul 20203:19 pmRNSForm 8.3 - CELLO HEALTH PLC
7th Jul 20203:00 pmBUSForm 8.3 - Cello Health Plc
7th Jul 202010:08 amRNSCELLO HEALTH PLC
7th Jul 20209:16 amPRNForm 8.3 - Cello Health Plc

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.